The SMC has approved aztreonam lysine for restricted use within this indication, when inhaled colistimethate sodium and inhaled tobramycin are not tolerated or not providing satisfactory therapeutic benefit (measured as ≥2% decline in FEV1). This advice takes account of the benefits of a Patient Access Scheme and is contingent upon its continuing availability (or a list price that is equivalent or lower).